Clinical Trials
32 trialsNCT05977998 2026-05-22
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04165096 2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06043323 2026-05-06
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04268498 2026-03-24
ADVANCE
University of Miami
Phase 2 Active not recruiting
NCT05896228 2026-03-11
Iber-KDd
University of Miami
Phase 2 Recruiting
NCT03913559 2026-02-12
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01391962 2026-02-02
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT07358689 2026-01-22
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
NCT01059786 2025-06-12
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03107182 2025-05-06
OPTIMA-II
University of Chicago
Phase 2 Completed
NCT04846348 2024-04-25
Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis
Mayo Clinic
Phase 2 Terminated
NCT04308837 2023-11-14
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Icahn School of Medicine at Mount Sinai
Phase 2 Unknown
NCT04660799 2023-10-12
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 2 Completed
NCT04189588 2023-10-06
versus
TerSera Therapeutics LLC
Phase 2 Completed
NCT05298683 2022-03-28
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
Phase 2 Unknown
NCT02999633 2022-03-21
ISLAY
Sanofi
Phase 2 Terminated
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00324467 2021-07-22
LYTPET
British Columbia Cancer Agency
Phase 2 Unknown
NCT00185692 2019-12-04
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
Phase 2 Completed
NCT02606994 2019-02-06
TPvsM
Oral Defense, LLC
Phase 2 Terminated
NCT01332630 2018-09-20
TPI 287 in Breast Cancer Metastatic to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01985126 2018-06-25
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD
Janssen Research & Development, LLC
Phase 2 Completed
NCT00482053 2018-05-14
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Phase 2 Terminated
NCT00186628 2017-11-28
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Stanford University
Phase 2 Completed
NCT00899847 2017-10-20
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
Stanford University
Phase 2 Completed
NCT00490009 2017-03-30
Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Stanford University
Phase 2 Completed
NCT01017731 2015-06-10
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Eli Lilly and Company
Phase 2 Completed
NCT00429702 2014-07-25
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
University of South Florida
Phase 2 Terminated
NCT00515073 2014-07-03
Papillary Serous Carcinoma of the Endometrium
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00887640 2014-02-26
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Duke University
Phase 2 Terminated
NCT00030992 2012-08-20
BMS 247550 to Treat Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed